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Summary.-The activity against murine anaplastic MT tumours ofthe chemothera-
peutic agent melphalan, either alone or in combination with one of 6 nitroimidazole
compounds, was assayed using an in vivo-in vitro tumour excision assay. The
melphalan alone proved cytotoxic to thetumour,whereas relatively little cytotoxicity
was produced by any of the nitroimidazoles alone. When the nitroimidazole were
given in combination with melphalan, dose-modifying potentiation ofits cytotoxicity
was observed. Maximum potentiation occurred when the nitroimidazoles were given
0-30minbefore the melphalan, althoughsome potentiationwas stillevidentwhenthey
were given up to 2 h before or after. There was no threshold in nitroimidazole dose
required to produce this potentiation, the degree of potentiation increrasing with
dose, albeit at a diminishing rate, to give maximum dose-modification factors of
about3.
The 6 nitroimidazole compounds in order of increasing effectiveness as
potentiators of melphalan activity were: METRO, Ro 05-9963, MISO, RSU 1047,
Ro03-8800 and Ro 03-8799. This order corresponds to the increasing electron affinity
ofthese compounds. The most effective compound here, Ro 03-8799, was about twice
as effective as the most widely used nitroimidazole in such studies, MISO.
TUMOUR HYPOXiA has long been
regarded as a critical factor in the response
of human tumours to radiotherapy. Only
relatively recently, however, have hypoxic
cells been suspected to be a resistant
subpopulation in tumour response to
chemotherapy (Sutherland, 1974; Hill &
Stanley, 1975; Sutherland et al., 1979;
Smith et al., 1979). Such resistance could
result from poor drug access, low rate of
cellular proliferation or biochemical
changes arising from the hypoxic state.
These considerations have prompted the
experimental evaluation of combinations
of various chemotherapeutic drugs with
agents that are selectively toxicto hypoxic
cells.
Misonidazole (MISO), currently under
clinical trial as a hypoxic cell radiosensi-
tizer, is also selectively toxic to hypoxic
cells both in vitro and in vivo (Hall &
Roizin-Towle, 1975; Brown, 1977). Fur-
36
ther, pretreatment in vitro ofhypoxic cells
with misonidazole renders the cells more
sensitive to the cytotoxic action of some
chemotherapeutic agents (Stratford et al.,
1980). Several in vivo studies have shown
that MISO apparently potentiates the
anti-tumour activity of some chemo-
therapeutic drugs, particularly alkylating
agents, in a variety of experimental
tumours (Clement et al., 1980; Rose et al.,
1980; Tannock, 1980; Siemann, 1981;
Stephens et al., 1981; Mulcahy et al., 1981;
Law et al., 1981; Martin et al., 1981;
Twentyman, 1981). It is not yet clear,
however, to what extent the in vitro
pretreatment effect contributes to the
potentiation observedinvivo.
The present work reports the poten-
tiating activity of some nitroimidazoles
including misonidazole on the anti-tumour
activity ofthe alkylating agent melphalan
in the murine anaplastic MT tumour. InP. W. SHELDON, E. L. BATTEN AND G. E. ADAMS
addition, the modified MT tumour clono-
genic assay now used routinely in our
laboratory is described.
MATERIALS AND METHODS
Mice and tumours.-The anaplastic MT
tumour implanted in inbred WHT/Cbi mice
was used throughout these studies. The mice
were obtained from the Institute's own colony
established in 1979 from a breeding nucleus of
WHT/GyfBSVS mice donated together with
the tumour by the Gray Laboratory. The
tumour has since been line-passaged i.m. in
our own inbred mice now designated WHT/
Cbi. The radiobiology of this tumour has
previously been studied in vivo by tumour-
control and growth-delay assays (Sheldon &
Hill, 1977), by subsequent monolayer cloning
(McNally & Sheldon, 1977) and by subsequent
soft-agar cloning (Stephens et al., 1980). In
the present work, a modified form of the last
technique was used.
The MT tumour was inoculated i.m. over
the sacral region of the backs of male mice.
This site was chosen rather than the more
conventional gastrocnemius muscle since
implantation in this site appeared to cause no
discomfort to the mice. When the tumours
attained a mean diameter of 6-8 mm (6-9
days after inoculation) the mice were selected
out for treatment.
Cytotoxic agents.-L-phenylalanine mus-
tard (Melphalan, Burroughs-Wellcome Ltd)
(5 nig in 0-25 ml of 2% HCI in ethanol) was
diluted as required with isotonic saline within
30 min of use. The melphalan was admin-
istered i.p. at 0 5 ml/25 g body wt.
The nitroimidazoles used were:
(i) MISO: misonidazole; 1-(2-hydroxy-3-
methoxypropyl)-2-nitroimidazole.
(ii) Ro 05-9963: desmethylmisonidazole; 1-
(2,3-dihydroxypropyl)-2-nitroimidazole.
(iii) Ro 03-8800: 1-(2-hydroxy-3-morpholino-
propyl)-2-nitroimidazole, hydrochloride.
(iv) Ro 03-8799: 1-(2-hydroxy-3-piperidino-
propyl)-2-nitroimidazole, hydrochloride.
(v) RSU 1047: 1-(2-hydroxy-4-morpholino-
butyl)-2-nitroimidazole.
(vi) METRO: metronidazole; 1-(2-hydroxy-
ethyl)-2-methyl-5-nitroimidazole.
Compounds (i)-(iv) were supplied by Dr
C. E. Smithen of Roche Products Ltd;
compound (vi) by May and Baker Ltd, and
compound (v) was synthesized by Dr I.
Ahmed in this laboratory. Each nitro-
imidazole compound was dissolved in warm
isotonic saline and, unless otherwise stated,
administered i.p. at 0 5 ml/25 g body wt.
Clonogenic assay.-Tumour response was
assayed by a modification of the soft-agar
cloning technique described by Stephens et al.
(1980). Eighteen hours after treatment,
individual tumours were excised, scraped free
of muscle, minced with curved scissors,
weighed, suspended in 10 ml PBS, 10 mg
trypsin and 0 5 mg DNase added, and rotated
at 120 rev/min for 20 min in a 37°C chamber.
A further 0-25 mg DNase was then added, the
suspension filtered through 35,um-pore poly-
ester mesh, centrifuged at 1000 rev/min for
5 min, resuspended in 10 ml Ham's F12
culture medium (supplemented with 15%
donor calf serum, 60 ,ug/ml sodium benzyl
penicillin, 100 ,ug/ml streptomycin sulphate,
and 50 ,g/ml neomycin sulphate) and refrac-
tile cells counted under a light microscope.
Dilutions of the single-cell suspensions for
measurement of their survival were based on
counts of large cells only (i.e. > 12 ,tm
diameter). The appropriately diluted cells,
together with 104 heavily irradiated feeder
cells and , 2 5 x 108 washed August rat
erythrocytes, were suspended in Iml aliquots
of 0.3% noble agar in Ham's F12 medium
(supplemented with 20% donor calf serum
and antibiotics as described above). Each
aliquot was plated into a 30mm diameter
plastic tissue-culture Petri dish containing a
solidified layer of 1 ml of0-5% noble agar in
Ham's F12 medium (supplement as per
aliquot). Nine replicate plates prepared from
each tumour were incubated for 13-15 days at
37°C in a humidified atmosphere of 5% 02,
5% CO2 and 90/ N2. The resulting tumour
colonies were counted using a low power
microscope. Only compact colonies of >50
cells were counted. The plating efficiency (PE)
of each tumour was calculated from the ratio
of the number of colonies counted to the
number of cells seeded.
RESULTS
In the course of the present study 22
untreated tumours were used as controls.
Because the tumours tended to grow into
the body cavity accurate palpation proved
difficult, and at excision the untreated
control tumour weights varied from 240 to
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FIG. 1.-The reduction in cell yield/g due to
melphalan. Different symbols represent
different experiment3; the curve was fitted
by eye.
450 mg. However, no dependence was
observed between either cell yield/g and
tumour weight or PE and tumour weight.
This also holds true even if the range is
extended from 180 to 570 mg. The mean
number ofcells harvested from the control
tumours was 1 1 x 108 cells/g (s.d.
2-7 x 107), and their subsequent PE on
incubation, 84% (s.d. 12%).
Relative to these control tumours, the
cell yield/g was reduced after melphalan
treatment, as shown by the scatter
diagram in Fig. 1. This reduction in cell
yield has been taken into account when
expressing tumour survival. In the present
studies, the survival has been expressed as
surviving fraction/g tumour =relative
PE x relative cell yield/g.
Fig. 2 shows the effect ofsingle doses of
melphalan (given 30 min after single doses
of saline) on the survival of the MT
tumour. The data, which show that
obtained for all the melphalan controls
done during the course of these experi-
ments (as depicted by the different
symbols), fit a survival curve computed by
linear regression using least-squares fit
analysis with N (extrapolation number)
set at unity. Although the effect of
melphalan was variable, it is evident that
the scatter around the dose-response line
occurred not from experiment to experi-
ment, but rather from variations in
individual tumour responsiveness. Conse-
quently this dose-response line has been
taken as the melphalan response for all
experiments. It indicates that the MT
tumour is sensitive to melphalan, a dose of
16 ,umol/kg reducing survival by adecade.
To evaluate the effect of the nitro-
imidazoles on this melphalan activity,
they were administered at various inter-
vals either before, or after, the melphalan.
Control experiments in which saline only
was given up to 3 h before or after the
melphalan showed no change in the
activity of the drug; indeed, similar
activity was observed when the saline dose
was omitted. However, each of the 6
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FIG. 2.-The dose response of melphalan
activity against the MT tumour. Each
datum point represents one tumour,
different symbols representing different
experiments.
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FIG. 3.-Maximum cytotoxicity occurred
when each of the 6 nitroimidazole
compounds (at 2-5 mmol/kg i.p.) were
given 0-30 min before melphalan (at 16
,umol/kg i.p.). Dashed lines: survival after
melphalan only (derived from Fig. 2). Solid
lines: survival afternitroimidazole givenbe-
foreoraftermelphalan (fittedbyeye). Differ-
entsymbolsrepresent different experiments.
nitroimidazoles, when given in combina-
tion with melphalan, reduced survival
further. Maximum cytotoxicity occurred
when the nitroimidazole was given
0-30 min before the melphalan (Fig. 3). To
economize on the number of mice, full-
time courses weie obtained only for MISO
and 8799. With these compounds in-
creased cytotoxicity still occurred when
they were given up to 2 h before, or after,
the melphalan.
Fig. 4 shows dose-response curves for
the nitroimidazoles given at 2*5 mmol/kg
30 min before the melphalan (or saline in
lieu). The data have been fitted to linear
regression lines, with N set for each
compound at the geometric mean survival
after nitroimidazole treatment only.
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MELPHALAN (,umoles/kg)
Fia. 4.-Dose-modifying potentiation of mel-
phalan activity by each of the 6 nitroimi-
dazoles (at 2-5 mmol/kg i.p.) given 30 min
before. Different symbolsrepresent different
experiments, but for clarity the symbols for
melphalan only activity (dashed lines)
have been omitted as previously shown in
Fig. 2. The solid lines were fitted by linear
regression with N set at geometric mean of
nitroimidazole alone toxicity. DMFs from
slope ratios are shown.
Although the values of N did not differ
significantly between compounds (range:
0-78 for 1047 to 0-56 for 8799), the mean
value for all compounds at 0-68 + 0 03 (s.e.
mean) does indicate that they did produce
significant toxicity to 30% of the cell
population. The linear regression lines,
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FiG. 5.-Potentiation of melphalan activity
(16 Zmol/kg) increased with nitroimidazole
dose (given immediately before). Dashed
line: melphalan only activity derived from
Fig. 2. Solid line: fitted by eye through data
points indicating no threshold dose.
Different symbols represent different
experiments.
originatingfromtheindividualvaluesofN,
indicate that the effect of the nitro-
imidazole in combination with melphalan
was dose-modifying. The dose-modifica-
tion factors (DMF) range from 1-6 for
metronidazole to 2-2 for 8799.
Fig. 5 shows that although the potentia-
tion of melphalan activity increases with
misonidazole dose, the rate of increase
falls. For the compound 8799 given at
three-quarteers of the LD50 dose, the
maximum DMF is 3. In all cases there
was no evidence for a threshold dose since
the response curves appear to extrapolate
back to the survival fraction for the saline-
plus-melphalan control (horizontal dotted
line).
ER DMF
2-0 -2-0
1-5
- -~~~~~~~~~~~~~~~~1-5
Cmpd MET 9963 MIS 1047 8800 8799
mg/g 0-43 0-47 050 0-67 0-73 0-72
mol.wt 171 187 201 270 293 291
E -486 -389 -389 -375 -368 -346
P 0-96 0 11 0-43 0.34 0-37 8-5
pKa - - - 6-65 6-15 8-71
0D 0-96 0-11 0 43 0-29 035 0 40
FIG. 6.-Comparison of the potentiation by
equimole doses of nitroimidazole given 30
minbefore melphalan (derived from Fig. 4).
Full histograms represent ERs at 10-3
survival, smaller hatched histograms
the DMFs from slope ratios; the difference
reflects the nitroimidazole-only cytotoxi-
city. Potentiation may increase with
increasing electron affinity (El7); the dis-
tribution coefficients at pH 7-4 (D) are
similar-as calculated from the pKa and
partition coefficient measured ofun-ionized
form (P).
DISCUSSION
The 6 nitroimidazoles investigated
here are known to be effective hypoxic-
cell radiosensitizers for the MT tumour
(Sheldon & Hill, 1977; Adams et al., 1982).
They are also selectively toxic to hypoxic
cells invitro (Adams etal., 1980; Stratford,
personal communication). In the present
work, the compounds when administered
singly at 2-5mmol/kgreducedMTtumour-
cell survival in situ by about 30% (Fig. 4).
This amount ofcell kill is probably greater
than might be expected on the basis of
hypoxic-cell toxicity only. While the
hypoxic fraction ofthe MT tumour has not
been measured for the present implanta-
tion site, it is only 5% in sacral s.c.
tumours (McNally & Sheldon, 1977) and
7% in thigh i.m. tumours (Stephens et at.,
1980). Ifthehypoxicfraction forthe sacral
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i.m. tumours is similar in magnitude, then
the 3000 drop in cell-surviving fraction
would imply some cytotoxic action against
oxic cells also. Brown (1977) has reported
that MISO alone was cytotoxic to 900% of
EMT6 tumour cells, although only 300o
were radiobiologically hypoxic.
Although the cytotoxic effects of the
nitroimidazoles are significant, they are
very small compared with the cytotoxic
effect of melphalan alone. The large
increase in cell kill observed for the
combined treatment ofnitroimidazole and
melphalan compared with melphalan
alone is clearly much greater than could be
accounted for simply in terms ofadditivity
of cell kill by each agent acting indepen-
dently. The relative effectiveness of the
nitroimidazoles as potentiators of mel-
phalan are compared in Fig. 6. The
administered doses ofeach compound were
chosen to achieve equimolar levels
(2.5 mmol/kg). The effectiveness of each
compound is defined in Fig. 6 as both
enhancement ratio (ER) and dose-modi-
fication factor (DMF). The ER is defined
as the ratio of the melphalan doses
required to give a surviving fraction of
1_0-3 and the DMF is the ratio ofthe linear
slopes of the respective survival curves.
The small difference between the values of
ER and DMF for a given drug reflects the
small but significant effect ofthe cytotoxic
effect of the nitroimidazole alone.
The table of physical-chemical proper-
ties in Fig. 6 shows values of one-electron
reduction potentials representative of
relative electronaffinities (E 17), octanol-
water partition coefficients (P) and, where
relevant, the pKa for the compounds. The
3 compounds 1047, 8800 and 8799 have a
basic function in their side chains and this
is reflected in their pKa values. :However,
all except 8799 are essentially un-ionized
at biological pH. Hence for all except 8799
the measured coefficients of the com-
pounds in their un-ionized form (P) are
similar to their calculated distribution
coefficients at pH 7-4 (D). Nevertheless,
the values of D for all compounds are
similar and no conclusions can be drawn
from these data in regard to the influence
of D on effectiveness of chemosensitiza-
tion. However, data for other compounds
without pKa considerations and covering
a substantially greater range of partition
coefficient (Sheldon & Batten, 1982;
Workman & Twentyman, 1982) indicate
that effectiveness can increase with
increasing lipophilicity.
Although it is known that hypoxic
cytotoxicity of nitroimidazoles in vitro
increases with electron affinity (Adams et
al., 1980), it is not known what influence
electron affinity has on the effectiveness of
a nitroimidazole to potentiate the activity
of chemotherapeutic agents. However, our
data in Fig. 6 do show that from left to
right the overall trend is for the enhance-
ment ratios to increase, and this does
correspond to an increase in electron
affinity of the compounds.
It has been reported previously that
maximum potentiation of melphalan
activity towards the Lewis lung carcinoma
occurred when MISO was given immedi-
ately before treatment with melphalan,
although some potentiation occurred when
given up to 2 h before or after (Rose et al.,
1980). In the MT tumour the timing
appeared less critical, full potentiation
occurring for all 6 of the nitroimidazoles
when given 0-30 min before the melphalan
(Fig. 3). For MISO and 8799 at least, some
potentiation was still evident when the
nitroimidazole was given up to 2 h before
or after the melphalan.
Consideration of the mechanism of this
potentiation will be dealt with in a
subsequent paper. Since greater potentia-
tion of melphalan activity has been
reported in tumours than dose-limiting
normal tissues (Rose et al., 1980; Clement
et al., 1980), a therapeutic gain may be
anticipated clinically. Although the nitro-
imidazole dose mainly used here
(2.5 mmol/kg) is approximately 3-fold that
clinically acceptable for MISO as a radio-
sensitizer (Dische et al., 1977), the absence
of a threshold dose (Fig. 5) suggests that
some potentiation may occur at clinically
acceptable doses. Indeed, as the magni-
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tude of this effect has been reported to
increase with prolonged contact time
(Brown & Hirst, 1982), the effect would be
expected to be greater clinically than here
because of the shorter half-lives of these
agents in mice than in man.
In conclusion, the present study has
shown that the activity of the alkylating
agent melphalan against the anaplastic
MT tumour can be potentiated by nitro-
imidazole compounds in a dose-modifying
manner. MISO, radiobiologically the most
commonly used nitroimidazole, was not
the most effective potentiator of mel-
phalan activity; of the 6 compounds
investigated in this paper, the most
effective compound was Ro 03-8799.
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